James K. Fong is CCO & VP at CTI BIOPHARMA CORP (CTIC). They have made 1 open-market trade across 1 company since 2023, most recently 2023-06-26.
CIK 0001916577
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTIC | 103,565 | $941K |
Shares reported on the most recent Form 4, priced at the 2023-01-26 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTIC | SELL | 2023-01-24 | 2023-01-26 | $6.00 | $600K | -2.3% | -3.9% | -13.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.